
Dragonfly chief: Bristol Myers shouldn’t blame IL-12’s clinical performance for decision to scrap the deal — economics played a key role
Bristol Myers Squibb says the IL-12 drug they were developing out of Dragonfly Therapeutics was scrubbed from the pipeline for a simple reason: It didn’t measure up on clinical performance.
But Bill Haney, the CEO of Dragonfly, is taking issue with that.
The early-stage drug, still in Phase I development, has passed muster with Bristol Myers’ general clinical expectations, advancing successfully while still in Phase I, he says.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.